Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2023-04-18 22:59
Recently, Healthy Yuan (600380.SH) released its 2022 annual report. During the reporting period, the company achieved revenue of 17.143 billion yuan, a year-on-year increase of 7.8%, net profit attributable to shareholders of the parent company reached 1.503 billion yuan, a year-on-year increase of 13.1%, and non-net profit reached 1.419 billion yuan, a year-on-year increase of 15.8%. In the same period, the cash flow generated from operating activities reached 3.978 billion yuan, a significant increase of 55.19% year-on-year.
Time Posted：2023-04-12 20:13
Health Yuan (600380.SH) disclosed its annual report on April 11, 2023. In 2022, Health Yuan achieved total operating revenue of 17.143 billion yuan, a year-on-year increase of 7.8%; net profit attributable to shareholders of the parent company reached 1.503 billion yuan, a year-on-year increase of 13.1%; earnings per share were 0.79 yuan. It is worth noting that, since 2018, Health Yuan's net profit attributable to shareholders of the parent company has achieved steady growth for five consecutive years, successfully doubling.
Time Posted：2023-04-10 19:49
Recently, Healthy Yuan and Lizhu Group held a donation ceremony for drugs in Kashgar, Xinjiang Uygur Autonomous Region, as part of a public welfare chronic disease prevention and treatment project. The ceremony was attended by the Deputy Mayor of Kashgar, representatives from the Kashgar Municipal Health Commission, Kashgar Municipal Bureau of Rural Revitalization, Kashgar Red Cross Society, and various township health centers in Kashgar, along with Healthy Yuan Group volunteers and local poverty-stricken households and monitored households.
Time Posted：2023-04-06 20:15
Recently, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare") and TaiGen Biotechnology Corporation and TaiGen Pharmaceutical R&D (Beijing) Co., Ltd. (hereinafter referred to as "TaiGen") signed an exclusive license agreement for the latter's development of the influenza antiviral drug TG-1000 in Greater China. According to publicly available information, TaiGen is a biotechnology company focusing on the research and development of anti-infective drugs,
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.